Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis currently manages 2 pending office actions within the Medical Devices & Mechanical Engineering technology area. This portfolio is distributed across 2 distinct art units, indicating a focused but multi-disciplinary examination path. The presence of 2 distinct examiners suggests that each pending matter is being handled by a different individual, preventing any single examiner from dominating the current prosecution landscape.
OGLES, MATTHEW ERIC is identified as the busiest examiner for this entity, currently overseeing 1 pending office action. This represents half of the total 2 pending office actions for the organization. Practitioners should note that while the volume is low, the distribution across 2 distinct art units may require diverse technical arguments to satisfy the specific requirements of each unit. The 1 pending action under the busiest examiner indicates a highly decentralized workload where no single official holds a majority of the active cases.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| JACKSON III, WALTER | 1 | 50.0% | +0.0% |
| DAVIS, JASON GREGORY | 1 | 74.2% | +18.2% |
| SHUPE, ELIZABETH A | 1 | 65.8% | +45.5% |
| WEBB, WALTER E | 1 | 46.3% | +18.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923671 | FLUID INJECTION DEVICE FOR INJECTING A FLUID BEHIND THE TYMPANIC MEMBRANE | DAVIS, JASON GREGORY | 167d overdue |
| 18836940 | AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER | AGGARWAL, SAHIL CHANDER | — |
| 18708092 | DGAT1/2-INDEPENDENT ENZYME SYNTHESIZING STORAGE LIPIDS (DIESL) | JACKSON III, WALTER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923671 | FLUID INJECTION DEVICE FOR INJECTING A FLUID BEHIND THE TYMPANIC MEMBRANE | DAVIS, JASON GREGORY | 167d overdue |
| 17619076 | SODIUM THIOSULFATE GEL FOR PREVENTING OR REDUCING HEARING LOSS | WEBB, WALTER E | 12d |
| 17909553 | MODULATING ANTI-TUMOR IMMUNITY | SHUPE, ELIZABETH A | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1638 | 1 |
| 3745 | 1 |
| 1643 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836940 | AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER | AGGARWAL, SAHIL CHANDER | 1623 | §102§103 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18708092 | DGAT1/2-INDEPENDENT ENZYME SYNTHESIZING STORAGE LIPIDS (DIESL) | JACKSON III, WALTER | 1638 | §102§103§112 | Non-Final OA | — | Pending | May 07, 2024 |
| 17923671 | FLUID INJECTION DEVICE FOR INJECTING A FLUID BEHIND THE TYMPANIC MEMBRANE | DAVIS, JASON GREGORY | 3745 | §102§103§112 | Non-Final OA | 167d overdue | Pending | Nov 07, 2022 |
| 17909553 | MODULATING ANTI-TUMOR IMMUNITY | SHUPE, ELIZABETH A | 1643 | §103 | Final Rejection | — | Pending | Sep 06, 2022 |
| 17619076 | SODIUM THIOSULFATE GEL FOR PREVENTING OR REDUCING HEARING LOSS | WEBB, WALTER E | 1612 | §103 | Final Rejection | 12d | Pending | Dec 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Sahil Chander Aggarwal has the most, with 1 of Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
